Clinical Trials Logo
  1. Home
  2. Polycystic Liver Disease
  3. NCT01354405

Somatostatin Analogues as a Volume Reducing Treatment of Polycystic Livers (RESOLVE) — RESOLVE  

Polycystic Liver Disease Clinical Trial

Official title:
The Effect of Lanreotide on Volume of Polycystic Liver and Kidney in Autosomal Dominant Polycystic Kidney Disease

Clinical Trial Summary

The aim of this study is to determine the effect of Lanreotide on polycystic liver and kidneys in patients with autosomal dominant polycystic kidney disease.

Clinical Trial Description

The aim of this single center observational study is to assess the effect of lanreotide on polycystic liver and kidney. This is achieved by assessing total liver and kidney volume, and several urinary markers that could predict kidney damage or kidney dysfunction, such as GFR, blood pressure, and urinary tubular damage markers and serum biomarker FGF23.

The investigators aim to include 43 patients affected by a polycystic liver due to ADPKD. The duration of the trial will be 28 weeks. The treatment will be 24 weeks and the first screening visit will take place four weeks before start of treatment. Eligible patients will be invited to participate. ;

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01354405
Study type Observational
Source Radboud University
Contact
Status Completed
Phase N/A
Start date May 2011
Completion date June 2014
View Details
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT05215964 - The Association Between Skeletal Muscle Mass and Severity of Polycystic Liver Disease and Polycystic Kidney Disease
Completed NCT00565097 - Lanreotide as Treatment of Polycystic Livers Phase 2/Phase 3
Recruiting NCT05500157 - Assessment of Treatment With Laparoscopic Fenestration or Aspiration Sclerotherapy for Large Symptomatic Hepatic Cysts N/A
Completed NCT01315795 - Lanreotide Autogel in the Treatment of Symptomatic Polycystic Liver Disease Phase 2/Phase 3
Active, not recruiting NCT05281328 - A Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With PLD Phase 2/Phase 3
Recruiting NCT02173080 - Development and Assessment of The Polycystic Liver Disease Questionnaire (PLD-Q).
Completed NCT01157858 - Everolimus and LongActing Octreotide Trial in Polycystic Livers Phase 2
Recruiting NCT05478083 - A GnRH Agonist IN Pre-menopausal Women STudy to Treat Severe Polycystic Liver Disease Phase 2
Recruiting NCT04645251 - Polycystic Liver Disease Registry (UK)
Completed NCT00426153 - Octreotide in Severe Polycystic Liver Disease Phase 2/Phase 3
Terminated NCT00934791 - Polycystic Liver Disease in Kidney Transplant N/A
Completed NCT02021110 - Ursodeoxycholic Acid as Treatment for Polycystic Liver Disease Phase 2
Completed NCT01670110 - Pasireotide LAR in Severe Polycystic Liver Disease Phase 2
Active, not recruiting NCT00771888 - Open-Label Extension of LOCKCYST Trial Phase 2/Phase 3
Recruiting NCT03960710 - Automatic Segmentation of Polycystic Liver